环孢素A在干眼治疗中的研究进展  

Advancements in the application of cyclosporine a for dry eye treatment

作　　者：夏桂媚 牛晓光[1] 吴淑娟 官凡钰 徐曼[1] Xia Guimei;Niu Xiaoguang;Wu Shujuan;Guan Fanyu;Xu Man(Wuhan Aier Ophthalmology Hanyang Hospital,Wuhan 430050,Hubei Province,China;Shenzhen Aier Eye Hospital,Shenzhen 518032,China)

机构地区：[1]武汉大学附属爱尔眼科医院,430050 [2]深圳爱尔眼科医院,518032

出　　处：《临床眼科杂志》2024年第5期475-479,共5页Journal of Clinical Ophthalmology

基　　金：爱尔眼科集团科研基金(AF2104D12)。

摘　　要：干眼症是临床上常见的眼表疾病之一,其治疗一直是多年来临床研究的热点。最新研究认为,眼表保护性免疫调节机制破坏及炎症反应在干眼发生发展中起着关键作用,炎症和干眼互相促进,形成恶性循环,除了常规使用人工泪液、睑板腺按摩治疗外,抗炎治疗已成为打破干眼恶性循环的新趋势。传统抗炎药物如激素及非甾体类药物的长期使用对眼表造成损伤,而环孢素A作为一种免疫抑制剂,在数十年的干眼临床研究中体现了巨大优势,本文就环孢素A滴眼液在干眼治疗中的作用机制和临床研究进展进行综述。Dry eye syndrome,a prevalent ocular surface disorder,has remained a focal point of clinical research for many years.Recent studies suggest that disruptions in the protective immune regulation mechanism of the ocular surface and inflammatory responses play pivotal roles in its onset and progression.This inflammation and dry eye condition reciprocally exacerbate each other,resulting in a vicious cycle.Beyond the standard treatments of artificial tears and meibomian gland massage,anti-inflammatory therapy is emerging as a novel trend to break this malign cycle.Conventional antiinflammatory drugs,including steroids and non-steroidal medications,have long-term deleterious effects on the ocular surface.In contrast,cyclosporine A,as an immunosuppressive agent,has demonstrated considerable superiority in dry eye clinical research over decades.This article offers a comprehensive review of the mechanistic role and clinical research advancements of cyclosporine A eye drops in treating dry eye syndrome.

关 键 词：环孢素A 干眼症 免疫抑制 

分 类 号：R777.34[医药卫生—眼科]